Key clinical point: Adding aspirin to an anticoagulant and P2Y12 inhibitor in atrial fibrillation patients with a recent acute coronary syndrome or percutaneous coronary intervention event produced no net benefit for patients.
Major finding: Serious bleeding events occurred in 1% more patients on aspirin, compared with placebo, while cutting serious ischemic events by 0.9%.
Study details: A post hoc, secondary analysis of data from AUGUSTUS, a multicenter, randomized trial with 4,614 patients.
Disclosures: AUGUSTUS was sponsored by Bristol-Myers Squibb and Pfizer, the companies that market apixaban. Dr. Alexander has been a consultant to and received research funding from Bristol-Myers Squibb and Pfizer; has been a consultant to AbbVie, Bayer, CryoLife, CSL Behring, Novo Nordisk, Portola, Quantum Genomics, XaTek, and Zafgen; and has received research funding from Boehringer Ingelheim, CryoLife, CSL Behring, GlaxoSmithKline, and XaTek. Dr. Indik had no disclosures.
Alexander JH et al. ACC 2020, Abstract 4090-08.